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Background: Hepatitis C virus (HCV) is one of the major infectious disease agents among 
injecting drug users (IVDUs). However, most of the IVDUs are not still treated.
Objectives: To examine the treatment course, adherence, tolerability and safety profiles 
and SVR rates in IVDUs compared to non-IVDUs.
Patients and Methods: Demographic and clinical data were collected from medical re-
cords of 345 adult patients diagnosed with chronic hepatitis C (CHC) who were treated 
with a peG-IFn-α and ribavirin in Croatian Reference Center for Viral Hepatitis in Zagreb 
between January 2003 and January 2010. efficacy, safety and tolerability treatment pro-
files were analyzed in IVDUs vs. non-IVDUs. positive predictors for treatment outcome 
were evaluated by univariate and multivariate logistic regression.
Results: A total of 106 (30.46%) IVDUs were identified. The IVDUs were mainly male (81.13% 
vs. 52.30%, P = 0.0001), young (mean ± SD age: 32.46 ± 5.33 y vs. 46.12 ± 11.48 y, P = 0.0001), 
had lower fibrosis and HAI score (measured by ISHAK) and shorter duration of infection 
(mean ± SD: 8.98 ± 5.87 vs. 16.79 ± 8.99 y, P = 0.0001) compared to non-IVDU group. In 
IVDUs, genotype 1a (24.52%) and 3a (38.68%) were predominant. There were no differenc-
es in completion rate between the two studied groups. IVDUs achieved a significantly 
higher rate of overall SVR (70.75% vs. 51.04%, P < 0.0009) and in genotypes 1 and 4 (65.08% 
vs. 48.73%, P = 0.0294) vs. non-IVDUs. Treatment discontinuation rates due to side-effects 
were not significantly different in IVDUs and non-IVDUs (2.83% vs. 7.11%, P = 0.1390). IVDU 
group had a higher rate of lost to follow-up (13.21% vs. 4.60%, P = 0.0071). There were no 
statistically significant differences in SVR rate between IVDUs with, or without substitu-
tion therapy (55.55% vs. 74.62%, P = 0.0866). Independent predictors of SVR were age < 40 
years and genotypes 2 and 3. Type of peG-IFn-α used was not associated with SVR. 
Conclusions: Treatment of CHC in IVDUs should strongly be encouraged as they have posi-
tive predictors for achieving SVR such as younger age, shorter duration of infection, and 
consequently favorable histological stage of the disease, and good adherence to treat-
ment. There is no difference in safety and tolerability profiles of treatment in IVDUs com-
pared to patients with no history of drug abuse. 
 Implication for health policy/practice/research/medical education:
This study evaluate the prevalence of hepatitis C among injecting drug users. We highly recommended the gastroenterologists and 
virologists to study this article.
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1. Background
The disordered life-style of many intravenous drug us-
ers (IVDUs) represents a serious health risk and is strong-
ly associated with social disadvantages. Sharing equip-
ment for drug injection is the most important factor for 
blood-borne  infection  transmission  (1).  IVDU  is  associ-
ated with high risk for transmission of human immuno-
deficiency virus (HIV) and hepatitis B (HBV) and C (HCV). 
HCV is far more infectious than HIV in terms of blood-
borne transmission, and shows much higher seropreva-
lence rates among IVDUs (1-3). Studies show that 60%–90% 
of patients with intravenous drug abuse are chronically 
infected with HCV. Incoming data reveals a prevalence of 
HCV among new IVDUs (injecting less than two years) of 
40%, making this problem a global public health prior-
ity (4-6). Currently available standard-of-care, pegylated 
interferon-alpha (peG-IFn-α) and ribavirin (RBV) therapy, 
successfully eradicates HCV infection in up to 55% of pa-
tients, as measured by sustained virological response 
(SVR) (7, 8). However, this treatment has numerous side 
effects, among which neuropsychiatric disorders play an 
important role in keeping adherence to the therapy (7, 8). 
Previous treatment guidelines and recommendations 
for the management of chronic hepatitis C (CHC) dis-
couraged treatment of HCV in IVDUs (9), but even after 
the guidelines have been liberalized over the past ten 
years, most of IVUDs are still not treated (10). Concerns 
about the abstinence, risk of reinfection, concomitant 
substitution therapy and alcohol abuse, and low treat-
ment compliance, are the main reasons for treatment 
denial (10, 11). only one-third of the infected former IV-
DUs receive antiviral treatment (10, 12). However, recently 
published studies contradict this prejudice by showing 
that IVDUs can be treated effectively and safely, especially 
those on methadone maintenance or similar opiate sub-
stitution therapy (13-15). Moreover, treatment of IVDUs 
becomes  imperative  for  every  efficient  public  health 
program. There can be no decrease in HCV prevalence in 
general population without management of infection in 
IVDUs. The reported prevalence rate of IVDU in european 
Union is estimated to be between 3.6 and 4.4 cases per 
1000 (in population aged 15–64 years), and the general 
decreasing trend has been noticed over the past ten years 
(4). Reports from Croatia show similar prevalence and 
stable epidemiological situation. Similar to some other 
european  countries,  Croatia  has  high  HCV  prevalence 
among IVDUs (4, 16-18). Kolaric, et al., reported the sero-
prevalence of anti-HCV  up to 65%, among imprisoned 
IVDUs in the three largest Croatian cities, representing 
a significant burden to Croatian health care system (16).
2. Objectives
This  study  was  conducted  to  examine  the  treatment 
course, safety and tolerability profile, adherence to treat-
ment and rates of SVR in IVDUs compared to non-IVDUs 
with CHC, treated at the Croatian Reference Center for Vi-
ral Hepatitis, the largest center for HCV-positive patients 
in Croatia.
3. Patients and Methods
A retrospective study including 345 adult patients, 211 
men (61.16%) and 134 women (38.84%), with a mean ± SD 
age of 41.92 ± 11.82 years, was conducted at the Croatian 
Reference  Center  for  Viral  Hepatitis,  Zagreb,  Croatia. 
A total of 106 IVDUs were recognized in the group, rep-
resenting 30.46% of those treated. A history of blood 
transfusion was a clear risk factor for HCV in 112 (32.46%) 
patients. A history of having been stuck with a bloody 
needle or sharp instrument (not IVDU-associated) was 
reported in 49 (14.2%) patients, sexual-behavior risk fac-
tors  in  7  (2.03%)  patients  and  the  risk  associated  with 
tattooing was reported in 1 (0.31%) patient. In 70 (20.28%) 
patients risk factor remained unknown. 
Two-hundred  and  one  (58.26%)  patients  were  treated 
with  peg-IFn-α2a  180  µg/week  +  RBV;  144  (41.74%)  were 
treated with peg-IFn-α2b 1.5 µg/week + RBV. RBV was ad-
ministered at the recommended dosage. The duration of 
therapy in genotypes 1 and 4 was 48 weeks, and in geno-
types 2 and 3 was 24 weeks. Therapy was discontinued in 
HCV genotype 1 and HCV genotype 4 patients if viral load 
decreased by less than 2 log HCV RnA copies/mL at week 
12 compared with baseline values or if HCV RnA was still 
detectable at week 24. In this study, we compared the 
age, gender, genotype, stage of fibrosis, type of peG-IFn-α, 
treatment safety profile and the sustained virological 
response (SVR) rates among IVDUs and patients with no 
history of drug use. The second objective of this study 
was to assess the influence of substitution therapy on 
achieving SVR in the group of IVDUs.
3.1. Definitions
SVR was defined as undetectable HCV RnA 24 weeks af-
ter therapy with combined peG-IFnα-2a or α-2b plus RBV. 
HCV RnA quantification was performed by using CoBAS 
Ampliprep/CoBAS TaqMan HCV test (Roche diagnostics, 
diagnostic  systems  pleasanton,  CA).  HCV  genotyping 
was performed by using VeRSAnT HCV Genotyping as-
say (LIpA) (Bayer diagnostics, puteaux, Cedex, France) at 
the Department of Molecular Diagnostics and Cellular 
Immunity, UHID. Liver biopsy was performed at the De-988 Chronic Hepatitis C in Drug Addicts Kurelac I et al.
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partment of Viral Hepatitis, UHID and the ISHAK scoring 
system was used to assess the histological activity (19). 
Disease duration was estimated by considering the date 
of blood transfusion received prior to 1993, the date of 
surgery, or the period of drug injection as the onset of 
infection. All the IVDUs treated at UHID were abstinent 
for at least six months, so the active drug users were not 
enrolled in our study.
3.2. Data Collection
Patient records of all patients that started treatment 
at UHID between January 2003 and January 2010 were 
extracted and used for collection of clinical and labora-
tory data. Ethics Committee of UHID approved this study. 
Virologic  results  and  liver  biopsy  data  were  double-
checked at the available databases of the Department of 
Molecular Diagnostic and Cellular Immunity, UHID, and 
Department for Viral Hepatitis, UHID.
3.3. Statistical Analysis
Statistical  analyses  were  performed  using  prism  (ver 
5.0) statistical software (Graphpad Software, San Diego, 
CA) and MedCalc for Windows®, ver 11.5.1.0 (MedCalc Soft-
ware, Mariakerke, Belgium). The demographic, clinical 
characteristics and laboratory data were evaluated and 
presented descriptively. χ2, Fisher’s exact test and Mann 
Whitney U test were used to compare the groups, as ap-
propriate. All tests were two-tailed; a P < 0.05 was consid-
ered statistically significant. Binary logistic regression 
analysis was used to assess the independent predictors 
of SVR. The strength of association was expressed as odds 
ratio (oR) and its corresponding 95% confidence interval 
(CI). The unadjusted univariate oR was also calculated 
for every predictor. All predictors were entered in a back-
ward stepwise logistic regression model with SVR being 
the dependent variable. The initial model included all 
predictors:  antiviral  therapy  (peg-IFn-α2a  vs.  peg-IFn-
α2b), age (≤ 40 years vs. > 40 years), gender, body weight 
(≤ 75 kg vs. > 75 kg), HCV-genotype (1 and 4 vs. 2 and 3), 
extent of fibrosis (mild fibrosis: ISHAK 0–2 vs. significant 
fibrosis: ISHAK 3–6), presence of risk factor (IVDU vs. non-
IVDU), and duration of infection. Statistically non-signifi-
cant predictors were progressively excluded based on a 
likelihood ratio test.
4. Results
4.1. Patients Characteristics
The  IVDUs  group  was  predominately  young  males 
with lower extent of fibrosis and HAI score (measured 
by ISHAK) and had typically a shorter duration of infec-
tion than non-IVDU group. There were significant differ-
ences in genotype distribution between the two groups: 
The genotype 1b was strongly associated with patients 
without history of drug abuse (transfusion and surgery), 
while in IVUDs genotypes 1a and 3a were predominant, 
with 3a being far more frequent than in other popula-
tions. The mean ± SD duration of IVDU abstinence was 
4.76 ± 3.16 (range: 0.5–18) years. The distribution of select-
ed variables is presented in Table 1.
Intravenous Drug Users 
(n = 106)
No History of Drug Abuse 
(n = 239)
P value
Demographic characteristics, no. (%)
Male
Female
Age, y, mean ± SD a
Weight, kg, mean ± SD
86 (81.13)
20 (18.87)
32.46 ± 5.33
78.94 ± 15.02
125 (52.30)
114 (47.70)
46.12 ± 11.48
73.57 ± 14.27
0.0001 b
0.0001 c
0.0129 c
Genotype, no. (%)
Total d
Subtype 1a
Subtype 1b
Subtype 2
Subtype 3/3a
Subtype 4
59 (55.66)
26 (24.52)
20 (18.87)
2 (1.87)
41 (38.68)
4 (3.79)
188 (78.66)
15 (6.27)
129 (53.97)
3 (1.25)
39 (16.32)
9 (3.77)
0.0001 b
0.0001 b
0.0001 b
0.6448 b
0.0001 b
0.5034 b
Liver biopsy (ISHAK score) (n = 262, 81+181)
Fibrosis; median (IQR a)
Histology activity score; median (IQR)
Duration of infection, y, mean ± SD
3 (3-3)
7 (6-9)
8.98 ± 5.87
3 (3-4)
8 (6-11)
16.79 ± 8.99
0.004 c
0.008 c
0.001 c
Therapy, no. (%) (n = 189, 83+106)
peG-IFn-α2a a
peG-IFn-α2b 
67 (63.20)
39 (36.80)
134 (56.07)
105 (43.93)
0.1917 b
Table 1. Baseline Characteristics of the patients With Chronic Hepatitis C enrolled in the Study
a Abbreviations: IQR, interquartile range; peG-IFn-α, pegylated interferon alpha; SD, Standard deviation 
b Fisher’s exact test
c Mann-Whitney U test
d In 57 patients genotype 1 was not typeable989 Chronic Hepatitis C in Drug Addicts Kurelac I et al.
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Intravenous Drug Users, No. (%) 
(n = 106)
No History of Drug Abuse, No. (%)
 (n = 239)
Anemia 19 (17.92) 45 (18.82)
neutropenia 7 (6.66) 26 (10.87)
Thrombocytopenia 5 (4.71) 19 (7.94)
Atralgiae/mialgiae 8 (7.54) 21 (8.78)
Dermatological (including dermatitis, rash, pruritus) 26 (24.52) 68 (28.45)
Hipo/hiperthyreosis 3 (2.83) 6 (2.51)
Flu-like symptoms 49 (46.23) 108 (45.18)
Respiratory symptoms 2 (1.88) 3 (1.25)
Anxiety 21 (19.81) 35 (14.64)
Depression 9 (8.49) 6 (2.51)
Insomnia 8 (7.54) 6 (2.51)
Headache 36 (33.96) 78 (32.63)
Table 2. Reported Side-effects During peG-IFn-α Therapy
4.2. Treatment Safety, Modifications and Discontinua-
tion
The safety and tolerability profiles of treatment were 
compared in IVDU and non-IVDU groups. Both groups 
had similar frequencies of side-effects (despite the dif-
ferent  response  rates  described  below).  Among  IVDU 
patients, 75 (70.75%) reported at least one side-effect, but 
only 12 of them (11.32%) required dose reduction and 3 
(2.83%) needed therapy discontinuation. Sixteen (15.09%) 
patients reported only one side-effect, 35 (33.33%) two, and 
24 (22.64%) three or more side-effects. Among patients 
with no history of drug abuse, 178 (74.47%) reported side-
effects, 38 (15.89%) required dose reduction and 17 (7.11%) 
needed therapy discontinuation. Twenty-six (10.87%) pa-
tients reported one, 64 (26.78%) two and 88 (36.82%) three 
or  more  side-effects.  The  frequency  of  most  common 
side-effects is shown in Table 2. next, we analyzed pos-
sible safety differences IVDU patients treated with two 
different  peG-IFn-α regiments. Regarding psychiatric 
side-effects, it was recorded that anxiety, depression and 
insomnia were more frequent in IVDU group, although it 
did not reach a statistically significant level (Table 2)
psychiatric side-effects were more frequent in patients 
treated with peG-IFn-α2a, but there were no statistically 
significant differences in general and psychiatric side-
effects. Among IVDUs treated with peG-IFn-2α, 14 (20.89%) 
patients reported anxiety problems, 6 (8.95%) insomnia 
and 8 (11.94%) depression. In IVDUs treated with peG-IFn-
2αb, 7 (17.94%) reported anxiety problems, 2 (5.13%) insom-
nia  and  one  depression  (2.56%).  Moreover,  correlation 
analysis did not reveal any association between the type 
of  peG-IFn  administered  and  therapy  modification  or 
discontinuation (oR = 1.87; 95% CI: 0.74–4.42; P = 0.1441). 
However, the influence of relatively small sample of pa-
tients within analyzed variables cannot be excluded.
Analysis of the reduction of therapy was evaluated in all 
345 patients (Table 3). There were no statistically signifi-
cant differences in reduction and discontinuation rates 
between the two groups. The reasons for treatment dis-
continuation in IVDU group were severe anemia, neutro-
penia and severe depression that did not improve after 
dose reduction and supportive therapy.
4.3. Virological Response
Analysis included data from all patients who received 
at least one dose of medication (intention-to-treat analy-
sis). In the whole group, SVR was achieved in 197 (57.10%) 
of 345 patients, SVR rate for genotypes 1 and 4 was 52.69% 
and for genotypes 2 and 3 was 74.11% (Table 3). 
To determine influence of previous intravenous drug 
use on achieving SVR, IVDUs and non-IVDUs groups were 
compared. overall, IVDUs group had a higher SVR rate 
(70.75% vs. 51.04%, P = 0.0009), particularly in those with 
genotypes 1 and 4 (65.08% vs. 48.73%, P = 0.0294, Fisher’s 
exact test) when compared to non-IVDU group. Although 
the SVR rate was better in IVDU patients with genotypes 
2 and 3 than in non-IVDU patients, the difference was 
not  statistically  significant.  Additionally,  IVDU  group 
had a higher rate of lost to follow-up (13.21% vs. 4.60%, P 
= 0.0071), i.e. 13% of IVDUs did not come for final evalua-
tion 24 weeks after therapy. There was no statistically sig-
nificant difference in SVR rates between patients treated 
with peG-IFn-α2a and peG-IFn-α2b.
4.4. Inﬂuence of Substitution Therapy With Methadone/
Buprenorphine on Adherence and SVR
Data  for  substitution  therapy  were  available  for  94 
(88.68%) of 106 patients. There were no complete medical 
records for 12 patients. According to records, 12 (12.76%) 
patients  were  on  methadone-maintained  therapy,  15 
(15.96%)  were  on  buprenorphine,  and  67  (71.28%)  re-
ceived no substitution therapy. Duration of abstinence 
was shorter in patients receiving maintenance therapy 
(mean ± SD: 3.61 ± 2.33 vs. 5.41 ± 3.26 y, P = 0.0170). To de-
termine the influence of substitution therapy on treat-
ment course, SVR and lost to follow-up rates, were com-
pared in IVDUs receiving substitution therapy and those 
who did not receive substitution therapy. The treatment 990 Chronic Hepatitis C in Drug Addicts Kurelac I et al.
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Intravenous Drug Users, No. (%) No History of Drug Abuse, No. (%) P values b
SVR a all genotypes 75 (70.75) 122 (51.04) 0.0009
Genotypes 1 and 4 41 (65.08) 96 (48, 73) 0.0294
peG-IFn-α2a +RBV a
peG-IFn-α2b +RBV
peG-IFn-α2a +RBV
peG-IFn-α2b +RBV
26 (66.66)
15 (62.50)
-
-
-
-
56 (49.57)
38 (44.18)
Genotypes 2 and 3 34 (79.07) 29 (69.05) 0.3300
peG-IFn-α2a +RBV
peG-IFn-α2b +RBV
peG-IFn-α2a +RBV
peG-IFn-α2b +RBV
21 (75.00)
13 (86.66)
-
-
-
-
13 (61.69)
15 (75.00)
Lost of follow-up 14 (13.21) 11 (4.60) 0.0071
Therapy modification
Reduction of drug doses
peG-IFn-α a dose reduction
RBV dose reduction
peG-IFn-α and RBV dose reduction
Therapy discontinuation
12 (11.32) c
6 (5.66)
4 (3.77)
2 (1.89)
3 (2.83)
38 (15.89) d
14 (5,86)
19 (7.95)
5 (2.09)
17 (7.11)
0.3210
1.0000
0.1694
1.0000
0.1390
 
Table 3. Treatment Modification and Sustained Virological Response (SVR)
a Abbreviations: peG-IFn-α, pegylated-interferon alpha; RBV, ribavirin; SVR, sustained virological response
b Fisher’s exact test
c Reasons for treatment modification in IVDUs: anemia 4, neutropenia 3, hypothyroidism 2, depression 2, pancytopenia 1
d Reasons for treatment modification: anemia 14, neutropenia 8, thrombocytopenia 7, depression 5, hypothyroidism 4
completion rate was better in the former group. Howev-
er, patients on substitution therapy had lower SVR rates 
measured by intention-to-treat analysis, mainly because 
of a higher rate of lost to follow-up found in those who 
received substitution therapy (Table 4).
4.5. Predictors of SVR
Univariate and multivariate binary logistic regression 
analyses were performed to identify independent pre-
dictors of SVR (Table 5). Univariate analysis revealed five 
significant associations: patients’ age (< 40 years), geno-
types 2 and 3, extent of liver fibrosis (mild fibrosis: ISHAK 
1-2), duration of infection and risk factor IVDU. patients’ 
weight and type of peG-IFn-α were not associated with 
SVR in our model. However, using a multivariate logistic 
regression model (stepwise backward method) we came 
out to two indepent predictors of SVR—patients’ age < 40 
years and genotypes 2 and 3. The area under the receiv-
er-operating-characteristic curve in the fully adjusted 
binary logistic regression model (with the selected pre-
dictors) was 0.718, which indicates a good discriminatory 
accuracy.
5. Discussion
According to the World Health organization, the esti-
mated prevalence of HCV infection in general popula-
tion in Croatia is 1.4%, while in IVDUs it is up to 69% (16, 18, 
20). IVDUs represent significant part of the population 
treated at Croatian Reference Center for Viral Hepatitis, 
as 30.46% of treated patients in study period were pre-
vious IVDUs. Many patients with CHC who are active or 
past IVDUs are still excluded from treatment programs. 
However, results from our study confirm previously pub-
lished data which shows that IVDUs can be treated effec-
tively and safely (13, 15, 21). Also, our study showed that 
IVDUs have even higher SVR rates, most likely because 
they have positive predictors for achieving SVR such as 
younger age, shorter duration of infection, and lower fi-
Methadone/Buprenorphine Therapy 
(n = 27)
No Substitution Therapy 
(n = 67)
P value b
SVR (ITT analysis a), no. (%) 15 (55.55) 50 (74.62) 0.0866
SVR genotype 1 and 4 5 (38.46) 32 (72.72) 0.0442
SVR genotype 2 and 3 10 (71.42) 18 (78.26) 0.7046
Lost of follow-up, no. (%) 7 (25,92) 7 (10.44) 0.1050
Treatment completion rate, no. (%) 27 (100) 64 (95.52) c 0.5546
Table 4. Influence of Substitution Therapy on the Level of Adherence to Treatment
a Abbreviation: ITT, intention-to-treat analysis
b Fisher’s exact test
c In three patients treatment was discontinued991 Chronic Hepatitis C in Drug Addicts Kurelac I et al.
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brosis score.
Currently, in Western europe and the USA the genotype 
1b  is  strongly  associated  with  transfusion-related  HCV 
infection, while HCV in IVUDs is mainly associated with 
genotypes 1a and 3a (4, 22, 23). Genotype distribution 
among IVDUs in our study follows the previously report-
ed pattern. Additionally, the genotype distribution in 
this study in comparison with previously published data 
from our center shows an increasing trend in frequency 
of genotypes 1a and 1b in IVDUs (24). Similarly, authors 
from France reported a significant increase in prevalence 
of genotypes 1a and 3a in IVDUs during the last three de-
cades (25).
one of the main concerns when treating IVDUs is their 
adherence to treatment. The reported completion rate 
among IVDUs is around 70%, with significant differences 
among countries and medical centers (12). Treatment 
completion rate in our study was 97.17% in IVDUs, and 
92.89% in non-IVDU group. Additionally, treatment com-
pletion rate was better in patients receiving substitution 
therapy than in those who did not, although we noticed 
a higher rate of patients who were lost to follow-up in pa-
tients who received substitution therapy. patients were 
closely monitored during the treatment and coming for 
regular controls every four weeks in our center, and if 
they experienced any new side-effects they could contact 
us at any time. Additional follow-up was provided by psy-
chiatrist at centers for treatment of addiction. This could 
explain the very good adherence rate observed in IVDUs 
which was even higher than non-IVDU group. It has been 
shown that substitution therapy effectively reduces the 
opiate need, HIV risk behaviors and transmission, gen-
eral mortality and criminal behavior (26, 27). Methadone 
maintenance treatment (MMT) programs, which require 
regular contact with patients, presumably promote ad-
herence to antiviral treatment. There are several studies 
that promote positive effects of MMT therapy and show 
that comprehensive, on site model of drug abuse treat-
ment with CHC management has improved the SVR rate 
(14, 21, 26, 27). Meanwhile, IVDUs treated at specialized 
liver clinics without integral care model reported lower 
adherence and SVR rates (11, 12, 15).
Results from a recently published meta-analysis have 
shown  that  tolerability  of  CHC  treatment  in  IVDUs  is 
comparable  to  that  of  general  population,  with  rate 
of psychiatric side-effects being 2% (15). our study also 
showed that treatment with peG-InF-α and RBV is safe in 
IVDUs, but with close psychiatric monitoring. Safety and 
tolerability profiles in IVDU and non-IVDU group were 
similar,  with  psychiatric  side-effects  (anxiety,  depres-
sion and insomnia) were more frequent in IVDU group, 
although not at a statistically significant level. An inter-
esting point of our study is that, although there was no 
statistically significant difference in treatment modifi-
cation or discontinuation between two studied groups, 
a higher trend toward discontinuation was noticed in 
non-IVDU group than in IVDU group (7.11% vs. 2.83%, P = 
0.139). In an Italian study discontinuation rate due to se-
vere depression was 3.8%; in our study only 1.8% of IVDUs 
had to discontinue treatment for severe depression (14).
Recent studies suggested that IVDUs treated with peG-
IFn-α and RBV can achieve an SVR rate equivalent to that 
obtained in registration trials, with SVR rates ranging 
from 39% to 61% (12, 15, 28). Differences in SVR rates could 
be explained by different study design and inclusion of 
active IVDUs. In our study, SVR rate for IVDUs was 65.1% for 
genotypes 1 and 4, and 79.1% for genotypes 2 and 3, which 
was  higher  than  that  in  non-IVDU  group  (48.7%  and 
69.1%, respectively). Results of this study were somewhat 
similar to the study of Manolakopoulos, et al, where SVR 
rates were also higher than those in registration trials, 
with an SVR rate for genotypes 1 and 4 being 57.6%, and 
for genotypes 2 and 3 was 78.3%. Higher SVR rates in IVDU 
group can be explained by significantly higher propor-
tion of patients who were young, had shorter duration 
of infection, lower fibrosis score and higher percentage 
of genotypes 2 and 3 (21). The limitations of this study in-
cluded its retrospective nature, collection of data from 
a single institution, and a modest sample size. Although 
we present data from a single institution, our hospital is 
the Croatian Reference Center for Viral Hepatitis, where 
the majority of patients from all Croatia are treated. It 
was beyond the scope of this study to review every chart 
to determine what percentage of all IVDUs patients with 
CHC were evaluated for and offered HCV treatment. Inter-
estingly, the patients with longer abstinence period and 
who did not receive substitution therapy usually came to 
seek the treatment on their own decision, while patients 
Univariate Analysis Multivariate Analysisb
Crude Odds-Ratio (95% CIa) P value Adjusted Odds-Ratio (95% CI) P value
Patientsc 2.15 (0.97 – 4.78) < 0.0001 2.98 (1.50 – 5.84) 0.0017
Genotype 2 and 3 17.36 (4.09 – 73.62) < 0.0001 25.40 (3.44 – 194.82) 0.0016
Mild fibrosis (ISHAK score 0,1,2) 1.87 (0.79 – 4.42) 0.0149 - -
Duration of infection 0.96 (0.93 – 0.99) 0.0265 - -
Intravenous drug use (risk factor) 3.38 (1.17 – 9.73) 0.0236 - -
Table 5. positive predictors of Sustained Virological Response (SVR)
a Abbreviation: CI, confidence interval
b Complete data for 172 patients
c Age < 40 y992 Chronic Hepatitis C in Drug Addicts Kurelac I et al.
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receiving substitution therapy were recommended for 
the treatment by their psychiatrists. our data clearly sug-
gest that adherence of IVDUs was excellent which result-
ed in a high SVR rate. Treatment of CHC in IVDUs should 
strongly be encouraged as they present a group with fa-
vorable predictors for achieving SVR. Timing for therapy 
for patients with substitution therapy and adherence, as 
well as treatment of side effects, should be considered 
as an important goal of multidisciplinary approach. on 
the other hand, the awareness of successful treatment of 
HCV infection can be an important “turning” point in re-
ducing or stopping the substance abuse.
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